Company Profile

Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin’s lead product, VASCEPA® (icosapent ethyl) capsules, is available by prescription in the United States and an increasing number of other countries. For more information about VASCEPA® visit www.vascepa.com.

VASCEPA® (icosapent ethyl), capsules, was originally approved in 2012 to reduce severely elevated levels of triglycerides (500 milligrams per deciliter or higher), along with diet and exercise, in adult patients. This drug’s approval was expanded in 2019 as an adjunct to maximally tolerated statin therapy to reduce the risk of cardiovascular events in certain adults with elevated triglyceride levels of 150 milligrams per deciliter or higher and other cardiovascular risk factors. This is the first and only FDA approved drug to reduce cardiovascular risk in patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy. Statins are drugs used to treat elevated cholesterol levels and reduce the risk of cardiovascular events. VASCEPA® is a prescription medicine used along with certain medicines (statins) to reduce the risk of heart attack, stroke and certain types of heart issues requiring hospitalization in adults with heart (cardiovascular) disease, or diabetes and two (2) or more additional risk factors for heart disease.

VASCEPA® (icosapent ethyl) capsules are a single-molecule prescription product consisting of the omega-3 acid commonly known as EPA in ethyl-ester form. VASCEPA® is not fish oil, but is derived from fish through a stringent and complex FDA-regulated manufacturing process designed to effectively eliminate impurities and isolate and protect the single molecule active ingredient from degradation. VASCEPA®, known in scientific literature as AMR101, has been designated a new chemical entity by the FDA. Amarin has been issued multiple patents internationally based on the unique clinical profile of VASCEPA®, including the drug’s ability to lower triglyceride levels in relevant patient populations without raising LDL-cholesterol levels. For more information about VASCEPA® visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

If you are reporting an adverse event or product complaint, please email amarinmi@druginfo.com or call the Amarin Call Center at 1 855 VASCEPA.

» See important safety information about VASCEPA®
» See full prescribing information for VASCEPA®

Amarin reported primary results of the successful REDUCE-IT trial concurrent with presentation of these results at the 2018 Scientific Sessions of the American Heart Association on November 10, 2018 in Chicago, Illinois. Results can be found in our press release. Additional references to such results are provided in a slide presentation of such results and in our results investor presentation.

Amarin reported additional results of the successful REDUCE-IT trial at the American College of Cardiology’s 68th Annual Scientific Session. The press release on the data is here. Additional references to these results are provided in this slide presentation.

Amarin is headquartered in Dublin, Ireland. In the U.S., the company's office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").